Monopar Therapeutics (NASDAQ:MNPR) Announces Earnings Results, Beats Expectations By $0.12 EPS

Key Points

• Monopar Therapeutics reported an earnings per share (EPS) of ($0.35) for the quarter, surpassing expectations by $0.12 compared to the analysts' consensus of ($0.47).
• The company's stock price increased by $3.04 to reach $34.38 during midday trading, with a market capitalization of $210.42 million.
• Analysts have raised Monopar's rating from "sell" to "hold", with several firms issuing buy ratings and a consensus target price of $60.00.

Monopar Therapeutics (NASDAQ:MNPR - Get Free Report) issued its earnings results on Tuesday. The company reported ($0.35) EPS for the quarter, beating analysts' consensus estimates of ($0.47) by $0.12, Zacks reports.

Monopar Therapeutics Price Performance

Shares of Monopar Therapeutics stock traded up $3.04 during midday trading on Tuesday, hitting $34.38. 16,327 shares of the company were exchanged, compared to its average volume of 39,802. The firm has a 50 day simple moving average of $38.05 and a 200-day simple moving average of $37.90. The firm has a market cap of $210.42 million, a P/E ratio of -9.88 and a beta of 1.05. Monopar Therapeutics has a 52 week low of $2.15 and a 52 week high of $54.30.

Wall Street Analyst Weigh In

Several brokerages recently commented on MNPR. Wall Street Zen raised Monopar Therapeutics from a "sell" rating to a "hold" rating in a research note on Thursday, May 22nd. Chardan Capital began coverage on shares of Monopar Therapeutics in a research report on Monday, June 23rd. They issued a "buy" rating and a $60.00 target price for the company. Finally, Cantor Fitzgerald started coverage on shares of Monopar Therapeutics in a report on Monday, July 7th. They set an "overweight" rating and a $74.00 price target on the stock. Two research analysts have rated the stock with a hold rating and five have issued a buy rating to the company. According to MarketBeat, Monopar Therapeutics currently has an average rating of "Moderate Buy" and a consensus target price of $60.00.

Insiders Place Their Bets

In other Monopar Therapeutics news, Director Kim R. Tsuchimoto sold 8,904 shares of the business's stock in a transaction dated Monday, July 14th. The shares were sold at an average price of $40.00, for a total value of $356,160.00. Following the transaction, the director directly owned 11,486 shares in the company, valued at $459,440. The trade was a 43.67% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Christopher M. Starr sold 16,800 shares of the company's stock in a transaction dated Monday, July 14th. The stock was sold at an average price of $40.00, for a total transaction of $672,000.00. Following the sale, the director directly owned 5,173 shares in the company, valued at $206,920. This represents a 76.46% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 42,504 shares of company stock worth $1,700,160 over the last three months. 20.50% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Monopar Therapeutics

A number of large investors have recently bought and sold shares of MNPR. JPMorgan Chase & Co. boosted its stake in Monopar Therapeutics by 1,821.0% in the second quarter. JPMorgan Chase & Co. now owns 1,921 shares of the company's stock worth $69,000 after purchasing an additional 1,821 shares in the last quarter. Rhumbline Advisers bought a new stake in Monopar Therapeutics during the 2nd quarter worth about $209,000. Jane Street Group LLC acquired a new stake in Monopar Therapeutics in the 1st quarter valued at about $377,000. Goldman Sachs Group Inc. acquired a new stake in Monopar Therapeutics in the 1st quarter valued at about $673,000. Finally, Geode Capital Management LLC raised its stake in shares of Monopar Therapeutics by 99.7% in the second quarter. Geode Capital Management LLC now owns 96,919 shares of the company's stock worth $3,468,000 after acquiring an additional 48,379 shares during the last quarter. 1.83% of the stock is currently owned by institutional investors.

Monopar Therapeutics Company Profile

Monopar Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.